Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pira-VG
- Development stage
- Unknown
- Lead developer
- Sanrey Therapeutics
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Pira-VG is an oral fixed-dose combination tablet developed and marketed by Sanrey Therapeutics as a cognitive enhancer and neuroprotective agent. It contains three active ingredients: Ginkgo biloba extract (60 mg), piracetam (800 mg), and vinpocetine (5 mg). Ginkgo biloba and piracetam act synergistically to improve cerebral blood flow, enhance microcirculation, and protect neurons from oxidative stress and free radical damage. Piracetam, a cyclic GABA derivative, modulates neurotransmission (particularly cholinergic and glutamatergic systems) and restores neuronal membrane fluidity. Vinpocetine, a synthetic derivative of the vinca alkaloid vincamine, acts as a cerebral vasodilator and metabolic enhancer by inhibiting phosphodiesterase type 1 (PDE1) and blocking voltage-gated sodium channels, thereby increasing brain oxygenation and glucose utilization. Pira-VG is primarily indicated for the management of cognitive impairment, memory enhancement, and neurological disorders associated with aging or cerebrovascular insufficiency.
- Brand names
- Pira-VG
- Other names
- Ginkgo biloba + piracetam + vinpocetine
02
Targets
PDE1 (Phosphodiesterase 1)AMPAR (AMPA receptor)IKBKB (IKKβ)PTAFR (Platelet-activating factor receptor)SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on Pira-VG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pira-VG.